'A glimmer of hope': perceptions, barriers, and drivers for medicinal cannabis use amongst Australian and New Zealand people with endometriosis - a qualitative study

Previous quantitative research has shown that cannabis use, mostly illicit, is used for symptom management amongst those with endometriosis living in Australia or New Zealand, but the drivers and barriers for use of legal, medicinal cannabis in this population are currently unclear. This study sough...

Full description

Saved in:
Bibliographic Details
Main Authors: Justin Sinclair (Author), Jason Abbott (Author), Antonina Mikocka-Walus (Author), Cecilia Ng (Author), Jerome Sarris (Author), Subhadra Evans (Author), Mike Armour (Author)
Format: Book
Published: Bioscientifica, 2023-11-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_37e57d80b1ef450dbd5ca6e5ce00567b
042 |a dc 
100 1 0 |a Justin Sinclair  |e author 
700 1 0 |a Jason Abbott  |e author 
700 1 0 |a Antonina Mikocka-Walus  |e author 
700 1 0 |a Cecilia Ng  |e author 
700 1 0 |a Jerome Sarris  |e author 
700 1 0 |a Subhadra Evans  |e author 
700 1 0 |a Mike Armour  |e author 
245 0 0 |a 'A glimmer of hope': perceptions, barriers, and drivers for medicinal cannabis use amongst Australian and New Zealand people with endometriosis - a qualitative study 
260 |b Bioscientifica,   |c 2023-11-01T00:00:00Z. 
500 |a https://doi.org/10.1530/RAF-23-0049 
500 |a 2633-8386 
520 |a Previous quantitative research has shown that cannabis use, mostly illicit, is used for symptom management amongst those with endometriosis living in Australia or New Zealand, but the drivers and barriers for use of legal, medicinal cannabis in this population are currently unclear. This study sought to investigate, via online focus groups, the perceptions, barriers, drivers, and experiences associated with cannabis use, whether legal or illicit, amongst 37 Australians and New Zealanders, aged 18-55, with a medical diagnosis of endometriosis. Previous cannabis usage was not required to participate. Discussion topics included strategies employed to manage symptoms, exploration of current medications, previous use of cannabis for pain management, and interest in using medicinal cannabis as a management strategy. Participants with moderate-to-severe symptoms of medically diagnosed endometriosis reported inadequacies with their current medical and self-management strategies and were inclined to try medicinal cannabis, both as part of their medical management and as part of a clinical trial. Barriers to medicinal cannabis adoption identified in this cohort included high costs of legal cannabis products, lack of clarity and fairness in current roadside drug testing laws and workplace drug testing policies, concern over the impact of stigma affecting familial, social and workplace life domains, and subsequent judgement and the lack of education/engagement from their medical providers regarding cannabis use. Given the interest in medicinal cannabis and the reported lack of effective symptom management, clinical trials are urgently required to determine the potential role that medicinal cannabis may play in reducing the symptoms of endometriosis. 
546 |a EN 
690 |a endometriosis 
690 |a cannabis 
690 |a medicinal cannabis 
690 |a australia 
690 |a new zealand 
690 |a Reproduction 
690 |a QH471-489 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
655 7 |a article  |2 local 
786 0 |n Reproduction and Fertility, Vol 4, Iss 4, Pp 1-15 (2023) 
787 0 |n https://raf.bioscientifica.com/view/journals/raf/4/4/RAF-23-0049.xml 
787 0 |n https://doaj.org/toc/2633-8386 
856 4 1 |u https://doaj.org/article/37e57d80b1ef450dbd5ca6e5ce00567b  |z Connect to this object online.